BREAST CANCER

Neoadjuvant nivolumab and non–anthracycline containing chemotherapy produced promising pathologic complete response rates regardless of whether nivolumab was administered before or during treatment with carboplatin and paclitaxel in patients with stage I to IIB triple-negative breast cancer.

Findings from the ADAPTcycle trial suggest that endocrine therapy plus ovarian suppression can generate high response rates in patients with hormone receptor-positive early breast cancer, regardless of age.

Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.

The addition of atezolizumab to neoadjuvant trastuzumab plus pertuzumab (HP) and chemotherapy led to a numerical, but not statistically significant, increase in pathologic complete response vs HP/chemotherapy alone in patients with HER2-positive operable breast cancer.

Preliminary study results examining the bispecific antibody, CDK4/6 inhibitor, and hormone therapy combination in patients with advanced breast cancer were presented at SABCS.

Clinical, transcriptomic, and genomic differences that may contribute to aggressive tumor biology were observed between Latin-American and non-Hispanic White patients with breast cancer.

The MammaPrint and BluePrint tests may be able to predict which patients with HR-positive, HER2-negative breast cancer are most likely to respond to neoadjuvant chemotherapy.

Dr. Paolo Tarantino offers expert guidance on optimizing outcomes for patients with ER+/HER2-low metastatic breast cancer.

A comprehensive review of the safety and efficacy from a HER2-low subgroup analysis in the EMERALD Trial presented at SABCS 2023 and clinical implications in practice.

Dr. Paolo Tarantino discusses the current treatment landscape of ER+/HER2- low metastatic breast cancer and unmet needs.

Expert insights on improving outcomes in ER+/HER2- metastatic breast cancer patients with resistance mutations.

Dr. Hope Rugo discusses EMERALD subgroup analysis, safety, and efficacy in patients with coexisting resistance mutations.

Current treatment landscape in ER+/HER2- metastatic breast cancer and unmet needs in overcoming treatment resistance.

The brain-penetrant oral selective estrogen receptor degrader SIM0270 exhibited a favorable safety profile and early signals of antitumor activity in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer, including those with ESR1 mutations.

Identifying the impact of elacestrant in clinical practice for patients with ER+/HER2- metastatic breast cancer.

A comprehensive review of the safety, efficacy, and subgroup analysis of the EMERALD Trial.

A discussion of the disease state, current therapies, and treatment challenges in ER+/HER2- metastatic breast cancer.

Adjuvant ribociclib plus standard non-steroidal aromatase inhibitors improved invasive disease-free survival in HR-positive, HER2-negative early breast cancer, compared with nonsteroidal aromatase inhibitors alone.

Improvement in progression-free-survival was demonstrated across all relevant subgroups in patients with ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

Stephanie L. Graff, MD, discusses what a community oncologist should know about her presentation on the Signatera assay in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer after adjuvant abemaciclib and endocrine therapy.

Early findings from the DEBBRAH study suggest that fam-trastuzumab deruxtecan-nxki shows potential in treating patients with advanced HER2-positive, HER2-low breast cancer, including those with leptomeningeal carcinomatosis.

Datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy in patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.

Naomi Dempsey, MD, discusses her poster presented at the 2023 San Antonio Breast Cancer Symposium analyzing the correlation of the Breast Cancer Index and patient risk factors.

Accurately stratifying hormone receptor–positive, HER2-negative breast cancer using BluePrint and MammaPrint assays demonstrated comparable 3-year recurrence-free survival rates between Black and White patients despite disparities in the distribution of molecular subtypes.

Maintenance pembrolizumab plus olaparib did not improve progression-free or overall survival in patients with locally recurrent inoperable or metastatic triple-negative breast cancer.

Adding pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab with endocrine therapy demonstrated improvements pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer.

Patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer given abemaciclib for 2 years in addition to endocrine therapy demonstrated an association between ctDNA positivity and disease recurrence.

Patient-reported outcomes of the CAPItello-291 study of capivasertib plus fulvestrant showed a positive benefit-risk profile for the combination in patients with HR-positive, HER2-negative advanced breast cancer.

Senthil Damodaran, MD, PhD, discusses data from a phase 2 trial of futibatinib in patients with metastatic HR-positive/HER2-negative breast cancer with FGFR1 amplifications.